Edgewise Therapeutics Inc (EWTX) reported better-than-expected financial results for the third quarter of fiscal 2025. The company recorded an earnings per share (EPS) of $-0.39, surpassing Wall Street's consensus estimate of $-0.41 by $0.02. Revenue remained at $0.0B, aligning with analyst expectations.
The announcement highlights the company’s operational performance during the quarter, which may suggest stronger business fundamentals. Founded in Boulder, Colorado, Edgewise is a clinical-stage biopharmaceutical company focusing on innovative treatments for serious muscle disorders. Its lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor currently in late-stage clinical trials for Becker and Duchenne muscular dystrophies.
Edgewise will host its earnings conference call at 8:00 AM ET to discuss these results and provide further insights into its business performance. Investors are encouraged to review the full earnings release and listen to management commentary for comprehensive context regarding the quarter's performance and future outlook.
With a market cap of $1,807.73 and a trailing twelve-month EPS of $-1.56, Edgewise is positioned to continue its focus on precision medicine through its proprietary drug discovery platform, which targets key muscle proteins. Upcoming earnings are scheduled for May 5, 2026, with an EPS estimate of $-0.4605 and revenue also expected at $0.0B.